CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm Clinical Trial

Official title:

A Randomized Open Label Pilot Study of Clostridium Butyricum MIYAIRI 588 (CBM588) in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03922035
• Other study ID #: 18193
• Secondary ID: NCI-2018-0188618
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: April 18, 2019
• Est. completion date: December 24, 2024

Study information

• Verified date: February 2024
• Source: City of Hope Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot trial studies the side effects and how well CBM588 works in improving clinical outcomes in patients who have undergone donor hematopoietic stem cell transplant. Gut microbiota (formerly called gut flora) is the name given to the microbe (bacteria) population living in the intestine. Gut bacteria help the body to digest certain foods that the stomach and small intestine have not been able to digest. CBM588, may increase gut bacteria biodiversity, prevent recurrent symptoms of gastrointestinal toxicity (ranging from diarrhea to life-threatening inflammation of the colon).

Description:

PRIMARY OBJECTIVES:

I. In patients with hematologic malignancies who are undergoing standard reduced intensity conditioning regimen (RIC) prior to allogeneic stem cell transplantation, to evaluate the safety and feasibility of Clostridium butyricum CBM 588 probiotic strain (CBM588) treatment by assessing:

Ia. Type, frequency, severity, attribution, time course and duration of adverse events, including diarrhea, bloodstream/intestinal infections.

Ib. Patient compliance, the patients' ability to take CBM588 during the treatment period.

SECONDARY OBJECTIVES:

I. Compare the incidence and severity of adverse events (AE) among CBM588-treated and untreated patients, including diarrhea, bloodstream infections and intestinal infections.

II. Estimate overall survival (OS), cumulative incidence (CI) of chronic graft versus host disease (GVHD), relapse/progression, and non-relapse mortality (NRM) at 100 days, 6 months, 1 year and 2 years.

EXPLORATORY OBJECTIVES:

I. Compare gut microbiome diversity among CBM588-treated/untreated patients. II. Obtain a preliminary estimate of the possible association between gut microbiome diversity and bloodstream infections.

III. Characterize and compare graft versus host disease (GVHD) inflammatory biomarkers (presence, level) among CBM588-treated and untreated patients.

IV. Obtain preliminary estimates of gut microbiome diversity, as assessed by the inverse Simpson Index, in CBM588-treated/untreated patients.

V. Obtain a preliminary estimate of the possible association between gut microbiome diversity and acute GVHD cumulative incidence, including time to onset.

VI. Characterize and compare urinary uindoxyl sulfate, tryptophan and kynurenine levels between CBM588- treated and untreated patients.

VII. To obtain a preliminary estimate of gut microbiome diversity and calorie intake.

VIII. Characterize and compare impact of CBM588 administration on regulatory T cells (T regs) reconstitution between CBM588-treated and untreated patients.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I (CBM588): Patients receive standard peri-/post-transplant supportive care and CBM588 orally (PO) twice daily (BID) from day of admission to day 28 in the absence of disease progression or unacceptable toxicity.

ARM II (STANDARD OF CARE): Patients receive standard peri-/post-transplant supportive care.

After completion of study treatment, patients are followed up for 100 days and then up to 2 years.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 36
• Est. completion date: December 24, 2024
• Est. primary completion date: December 24, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Documented informed consent of the participant and/or legally authorized representative.

• Assent, when appropriate, will be obtained per institutional guidelines.

• Willingness to be followed for the planned duration of the trial (2 years).

• Karnofsky performance status must be >= 60%.

• Any hematologic disorders receiving allogeneic hematopoietic stem cell transplant with reduced intensity conditioning.

• Planned 8/8 or 7/8 (human leukocyte antigens [HLA]-A, B, C, DR) related or unrelated donor hematopoietic cell transplantation (HCT).

• Clinical Laboratory and Organ Function Criteria: Consistent with City of Hope (COH) standard operating procedure (SOP) for "patient evaluation for selection for hematopoietic cell transplantation.

• Patient is eligible to receive allogeneic hematopoietic cell transplantation with reduced intensity conditioning.

• Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the last dose of protocol therapy.

• Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only).

Exclusion Criteria:

• Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this pilot study. A legal guardian may substitute for the research participant.

• Refusing to use contraception up to 90 days post-HCT.

• Pregnant and/or breast feeding if a female recipient.

• Patients with history of chronic intestinal disease (e.g., Crohn's disease, ulcerative colitis).

• In the opinion of the principal investigator (PI), the participant has a condition that will preclude them from complying with study treatment.

• Research participants receiving any other investigational agents.

• Known or documented history of hypersensitivity to all the listed antibiotics, used for severe infections related to CBM588:

• Ampicillin.

• Chloramphenicol.

• Clindamycin.

• Erythromycin.

• Metronidazole.

• Tetracycline.

• Vancomycin.

• Research participants with presence of other active malignancy within 2 years of study entry. Participants with history of prior malignancy treated with curative intent who achieved complete response (CR) more than 2 years before study entry are eligible. This exclusion rule does not apply to non-melanoma skin tumors and in-situ cervical cancer.

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent (i.e., research participants whom are severe lactose intolerance or intolerance to milk products).

• Research participants having any uncontrolled illness including ongoing or active infection. Research participants with known active hepatitis B or C infection; research participants who are human immunodeficiency virus (HIV) seropositive based on testing performed within 4 weeks of enrollment; research participants with any signs or symptoms of active infection, positive blood cultures, or radiological evidence of infections.

• Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.

• Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).

Related Conditions & MeSH terms

• Hematologic Neoplasms
• Hematopoietic and Lymphoid Cell Neoplasm

Intervention

Other:
• Best Practice
Receive standard peri-/post-transplant supportive care

Drug:
• Clostridium butyricum CBM 588 Probiotic Strain
Given PO

Locations

Country	Name	City	State
United States	City of Hope Medical Center	Duarte	California

Sponsors (2)

Lead Sponsor	Collaborator
City of Hope Medical Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Gut microbiome diversity	Will be assessed by the inverse Simpson index. Will be compared among CBM588-treated/untreated patients and assessed by Fisher's exact test or two-sample Wilcoxon test whenever appropriate.	Up to 2 years
Other	Gut microbiome diversity and bloodstream infection	Incidence of bloodstream infections and infectious enterocolitis will be evaluated and a preliminary estimate of the association between gut microbiome diversity and blood stream infections will be obtained.	Up to 2 years
Other	Gut microbiome diversity aGVHD incidence	Will be obtained based on: 1) evaluation and comparison of presence and levels GVHD/inflammatory biomarkers including TNFR1, ST2, Reg3 alpha, TNF-alpha, IL-8 and TGF-beta 1 between the 2 study arms, and 2) incidence, site (gastrointestinal [GI], liver, and skin), severity (grade III-IV GI toxicity per the NCI CTCAE version 5 Scale) and time to onset of aGVHD among treated and untreated patients.	Up to 2 years
Other	Levels of tryptophan metabolites	Presence and levels of urinary uindoxyl sulfate, tryptophan and kynurenine (markers of GI GVHD complications) will be evaluated and compared between CBM588-treated and untreated patients.	Up to 2 years
Other	Impact on regulatory T cells (T regs)	Presence and levels T regs will be evaluated and compared in blood samples from patients among treated and untreated patients.	Up to 2 years
Primary	Incidence of adverse events	Will be scored according to the modified Bearman Scale and National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5 scale. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study treatment and reversibility or outcome.	From initiation of treatment until end of treatment assessed up to 100 days
Primary	Feasibility of CBM588	Will be evaluated by assessment of patients' ability to take half of the specified dose.	During the safety lead-in phase
Secondary	Incidence and severity of adverse events	Assessed by modified Bearman criteria and NCI CTCAE version 5 scale. Will be compared among CBM588 treated and untreated patients.	Up to 2 years
Secondary	Overall survival	Will be estimated using the product-limit method of Kaplan and Meier.	Up to 2 years
Secondary	Cumulative incidence (CI) of chronic graft versus host disease (cGVHD)	Will be estimated using the method described by Gooley et al (1999).	Up to 2 years
Secondary	CI of acute graft versus host disease (aGVHD)	Will be estimated using the method described by Gooley et al (1999).	Up to 2 years
Secondary	CI of relapse/progression of disease	Will be estimated using the method described by Gooley et al (1999).	Up to 2 years
Secondary	Non-relapse mortality	Will be estimated using the method described by Gooley et al (1999).	Up to 2 years